Exelixis
EXEL
#1590
Rank
HK$107.24 B
Marketcap
HK$426.66
Share price
2.22%
Change (1 day)
24.87%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): HK$24.45

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$24.54. In 2025 the company made an earnings per share (EPS) of HK$22.66.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$24.457.88%
2025HK$22.66
2023HK$5.1214.61%
2022HK$4.47-22.97%
2021HK$5.80100%
2020HK$2.90-65.09%
2019HK$8.31-53.91%
2018HK$18.04333.96%
2017HK$4.16-260.61%
2016-HK$2.59-58.75%
2015-HK$6.27-42.45%
2014-HK$10.905.3%
2013-HK$10.35

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
HK$68.51 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$10.27-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$113.55 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$20.07-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$27.90 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$27.92 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$30.48 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-HK$28.78-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-HK$6.59-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA